DIRECT ORAL ANTICOAGULANTS: A COMPARISON OF EFFICACY AND SAFETY, ERRORS IN THEIR APPLICATION, AND THE USAGE OF REVERSAL AGENTS


如何引用文章

全文:

详细

This review is devoted to updating the existing knowledge about pharmacology of the drugs from the group of direct oral anticoagulants (DOACs). Special attention is paid to comparison of the anticoagulant properties of DOACs with traditional (indirect) anticoagulants at various dosage regimens and to study drug interactions of DOACs with drugs from different pharmacological groups. Widely analyzed the side effects associated with errors in the application of DOACs and provided recommendations for their correction, including the using of reversal agents therapy. Based on this, the presented article will be useful to clinicians to familiarize themselves with modern medical strategies based on the use of drugs from the DOACs group for the prevention and treatment of diseases associated with increased blood clotting ability and using of DOACs specific antagonists for treatment overdose of DOACs.

作者简介

V. Tarasov

I.M. Sechenov First State Medical University (Sechenov University)

119991, Moscow, Russian Federation

Vladimir Chubarev

I.M. Sechenov First State Medical University (Sechenov University)

Email: tchoubarov@mail.ru
Ph.D, professor of the Department of Pharmacology «I.M. Sechenov First State Medical University (Sechenov University)», 119991, Moscow, Russian Federation 119991, Moscow, Russian Federation

E. Zykova

I.M. Sechenov First State Medical University (Sechenov University)

119991, Moscow, Russian Federation

A. Belosludtsev

I.M. Sechenov First State Medical University (Sechenov University)

119991, Moscow, Russian Federation

E. Mokshanova

I.M. Sechenov First State Medical University (Sechenov University)

119991, Moscow, Russian Federation

S. Sologova

I.M. Sechenov First State Medical University (Sechenov University)

119991, Moscow, Russian Federation

S. Lebedeva

I.M. Sechenov First State Medical University (Sechenov University)

119991, Moscow, Russian Federation

E. Grigorevskikh

I.M. Sechenov First State Medical University (Sechenov University)

119991, Moscow, Russian Federation

T. Zatsepilova

I.M. Sechenov First State Medical University (Sechenov University)

119991, Moscow, Russian Federation

N. Preferanskaya

I.M. Sechenov First State Medical University (Sechenov University)

119991, Moscow, Russian Federation

N. Musina

I.M. Sechenov First State Medical University (Sechenov University)

119991, Moscow, Russian Federation

D. Sologova

I.M. Sechenov First State Medical University (Sechenov University)

119991, Moscow, Russian Federation

参考

  1. Pradaxa Prescribing Information. Ridgefield, CT 06877 USA: Boehringer Ingelheim Pharmaceuticals Inc.; 2018. Available at: https://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf. (Accessed December 13, 2018)
  2. Российские клинические рекомендации по диагностике, лечению и профилактике тромбоэмболических осложнений (ВТЭО). Москва, Россия: ООО «Издательство Медиа Сфера»; 2015. Доступно на: http://webmed.irkutsk.ru/doc/pdf/pe2015.pdf (Дата обращения 29 Декабря, 2018)
  3. Villines T.С., Schnee J., Fraeman K., Siu K., Reynolds M.W., Collins J. et al. Comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system. Thromb Haemost. 2015; 114(12): 1290-98. doi: 10.1160/TH15-06-0453
  4. Stacy Z, Richter S. Practical Considerations for the Use of Direct Oral Anticoagulants in Patients With Atrial Fibrillation. Clinical and Applied Thrombosis/Hemostasis. 2016; 23(1): 5-19. doi: 10.1177/1076029616634886
  5. Ingrasciotta Y. Pharmacokinetics of new oral anticoagulants: implications for use in routine care. Expert Opin Drug Metab Toxicol. 2018; 14(10): 1057-69. doi: 10.1080/17425255.2018.1530213
  6. Xarelto Prescribing Information. Titusville, NJ 08560 USA: Janssen Pharmaceuticals Inc.; 2018. Available at: http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf. (Accessed January 4, 2019).
  7. Coleman C.I., Turpie A.G.G., Bunz T.J., Eriksson D., Sood N.A., Baker W.L. Effectiveness and safety of rivaroxaban vs. warfarin in non-valvular atrial fibrillation patients with a non-sex-related CHA2DS2-VASc score of 1. European Heart Journal - Cardiovascular Pharmacotherapy. 2018; 5(2): 64-9. doi: 10.1093/ehjcvp/pvy025
  8. Eliquis Prescribing Information. Plainsboro, NJ 08536 USA: Bristol-Myers Squibb Company; 2014. https://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM333723.pdf. (Accessed January 5, 2019).
  9. Rose M. Pharmacological profile of non-vitamin K antagonist oral anticoagulants. Afr J Pharm Pharmacol. 2017; 11(9): 125-36. doi: 10.5897/ajpp2017.4744
  10. Mavrakanas T., Samer C., Nessim S., Frisch G., Lipman M. Apixaban Pharmacokinetics at Steady State in Hemodialysis Patients. Journal of the American Society of Nephrology. 2017; 28(7): 2241-8. doi: 10.1681/asn.2016090980
  11. Barr D., Epps Q. Direct oral anticoagulants: a review of common medication errors. J Thromb Thrombolysis. 2018; 47(1): 146-154. doi: 10.1007/s11239-018-1752-9
  12. Tran E., Duckett A., Fisher S., Bohm N. Appropriateness of direct oral anticoagulant dosing for venous thromboembolism treatment. J Thromb Thrombolysis. 2017; 43(4): 505-13. doi: 10.1007/s11239-017-1487-z
  13. Savaysa (Edoxaban) Now Available In U.S. Pharmacies. Tokyo, Japan: Daiichi Sankyo Inc.; 2015. https://www.daiichisankyo.com/media_investors/media_relations/press_releases/detail/006247/20150209_559_E2.pdf. (Accessed January 13, 2019).
  14. Proietti M., Lip G. Edoxaban in venous thromboembolism and stroke prevention: an appraisal. Vasc Health Risk Manag. 2016;12:45-51. doi: 10.2147/vhrm.s81569
  15. Bevyxxa Prescribing Information. San Francisco, CA 94080 USA: Portola Pharmaceuticals; 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208383s000lbl.pdf. (Accessed January 23, 2019).
  16. Thoenes M., Minguet J., Bramlage K., Bramlage P., Ferrero C. Betrixaban - the next direct factor Xa inhibitor?. Expert Rev Hematol. 2016; 9(12): 1111-7. doi: 10.1080/17474086.2016.1256194
  17. Viprey M., Jeannin R., Piriou V., Chevalier P., Michel C., Aulagner G. et al. Prevalence of drug-related problems associated with direct oral anticoagulants in hospitalized patients: a multicenter, cross-sectional study. J Clin Pharm Ther. 2016; 42(1): 58-63. doi: 10.1111/jcpt.12473
  18. Whitworth M.M., Haase K.K., Fike D.S., Bharadwaj R.M., Young R.B., MacLaughlin E.J. Utilization and prescribing patterns of direct oral anticoagulants. Int J Gen Med. 2017; 2017(10): 87-94. doi: 10.2147/ijgm.s129235
  19. Larock A., Mullier F., Sennesael A., Douxfils J., Devalet B., Chatelain C. et al. Appropriateness of Prescribing Dabigatran Etexilate and Rivaroxaban in Patients With Nonvalvular Atrial Fibrillation. Annals of Pharmacotherapy. 2014; 48(10): 1258-68. doi: 10.1177/1060028014540868
  20. Basaran O., Basaran N.F., Cekic E.G., Altun I., Dogan V., Mert G.O. et al. PRescriptiOn PattERns of Oral Anticoagulants in Nonvalvular Atrial Fibrillation (PROPER study). Clinical and Applied Thrombosis/Hemostasis. 2015; 23(4): 384-391. doi: 10.1177/1076029615614395
  21. Гайсенок О.В., Леонов А.С. Применение пероральных антикоагулянтов у пациентов с фибрилляцией предсердий: данные когортного исследования. Рациональная Фармакотерапия в Кардиологии. 2016; 12(4): 376-9. https://doi.org/10.20996/1819-6446-2016-12-4-376-379
  22. Steinberg B.A., Shrader P., Thomas L., Ansell J., Fonarow G.C., Gersh B.J. et al. Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes. J Am Coll Cardiol. 2016; 68(24): 2597-2604. doi: 10.1016/j.jacc.2016.09.966
  23. Conway S.E., Hwang A.Y., Ponte C.D., Gums J.G. Laboratory and Clinical Monitoring of Direct Acting Oral Anticoagulants: What Clinicians Need to Know. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2017; 37(2): 236-48. doi: 10.1002/phar.1884
  24. Ciurus T., Sobczak S., Cichocka-Radwan A., Lelonek M. CARDIAC SURGERY New oral anticoagulants - a practical guide. Polish Journal of Cardio-Thoracic Surgery. 2015; 12(2): 111-8. doi: 10.5114/kitp.2015.52851
  25. Zehnder J. Clinical use of coagulation tests. Wolters Kluwer; 2019. https://www.uptodate.com/contents/clinical-use-of-coagulation-tests. (Accessed February 19, 2019).
  26. Siegal D., Konkle B. What is the effect of rivaroxaban on routine coagulation tests?. Hematology. 2014; 2014(1): 334-336. doi: 10.1182/asheducation-2014.1.334
  27. Praxbind Prescribing Information. Ridgefield, CT 06877 USA: Boehringer Ingelheim Pharmaceuticals Inc.; 2018. Available at: https://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Praxbind/Praxbind.pdf. (Accessed February 23, 2019).
  28. Sié P. Spotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran. Drug Des Devel Ther. 2016; 2016(10): 1683-9. doi: 10.2147/dddt.s94167
  29. Pollack C., Reilly P., Bernstein R., Dubiel R., Eikelboom J., Glund S. et al. Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran. Thromb Haemost. 2015; 114(07): 198-205. doi: 10.1160/th15-03-0192
  30. Reilly P., van Ryn J., Grottke O., Glund S., Stangier J. Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects. Am J Med. 2016; 129(11): 64-72. doi: 10.1016/j.amjmed.2016.06.007
  31. Pollack C., Reilly P., van Ryn J., Eikelboom J., Glund S., Bernstein R. et al. Idarucizumab for Dabigatran Reversal g - Full Cohort Analysis. New England Journal of Medicine. 2017; 377(5): 431-41. doi: 10.1056/nejmoa1707278
  32. Pollack C., Reilly P., van Ryn J., Eikelboom J., Glund S., Bernstein R. et al. Idarucizumab for Dabigatran Reversal - Supplementary Appendix. New England Journal of Medicine. 2015; 373(6): 511-20. doi: 10.1056/nejmoa1502000
  33. Tummala R., Kavtaradze A., Gupta A., Ghosh R. Specific antidotes against direct oral anticoagulants: A comprehensive review of clinical trials data. Int J Cardiol. 2016; 214: 292-8. doi: 10.1016/j.ijcard.2016.03.056
  34. Connolly S., Milling T., Eikelboom J., Gibson M., Curnutte J., Gold A. et al. Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. New England Journal of Medicine. 2016; 375(12): 1131-41. doi: 10.1056/nejmoa1607887
  35. Crowther M. Antidotes for Novel Oral Anticoagulants. Arterioscler Thromb Vasc Biol. 2015; 35(8): 1736-45. doi: 10.1161/atvbaha.114.303402
  36. Chai-Adisaksopha C. Hemodialysis for the treatment of dabigatran-associated bleeding: a case report and systematic review. Journal of Thrombosis and Haemostasis. 2015; 13(10): 1790-8. doi: 10.1111/jth.13117
  37. Hu T., Vaidya V., Asirvatham S. Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab. Vasc Health Risk Manag. 2016; 2016(12): 35-44. doi: 10.2147/vhrm.s89130
  38. Xarelto. Procedural Steps Taken And Scientific Information After The Authorisation. London, E14 5EU UK: European Medicines Agency; 2018. https://www.ema.europa.eu/en/documents/procedural-steps-after/xarelto-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf. (Accessed February 15, 2019).
  39. Grottke O., van Ryn J., Spronk H., Rossaint R. Prothrombin complex concentrates and a specific antidote to dabigatran are effective ex-vivo in reversing the effects of dabigatran in an anticoagulation/liver trauma experimental model. Critical Care. 2014; 18(1): R27. doi: 10.1186/cc13717
  40. Perzborn E., Heitmeier S., Laux V., Buchmüller A. Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro. Thromb Res. 2014; 133(4): 671-81. doi: 10.1016/j.thromres.2014.01.017
  41. Schultz N., Tran H., Bjørnsen S., Henriksson C., Sandset P., Holme P. The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII against anticoagulation of Xa inhibitor. Thromb J. 2017; 15(6). doi: 10.1186/s12959-017-0129-1
  42. Levy J., Levi M. New Oral Anticoagulant-Induced Bleeding. Clin Lab Med. 2014; 34(3): 575-86. doi: 10.1016/j.cll.2014.06.004

版权所有 © Eco-Vector, 2019


 


##common.cookie##